TORONTO, May 23, 2013 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation") today announced that Mr. Anthony Bihl has been appointed as the
Chairman of the board. The Corporation also notes that at the annual
and special meeting of shareholders that was held earlier today, all
eight nominees for the board were elected as a matter of corporate law,
however, two of the directors received a greater number of votes
withheld than votes in favour. Pursuant to the Majority Voting Policy
of the Corporation, those two directors have each tendered their
resignations as directors, effective only on acceptance by the board.
Full details are contained in the Report of Voting Results for the
Meeting which has been filed on Sedar at www.Sedar.com.
Pursuant to the Majority Voting Policy, the board has convened and
referred the resignations to an ad hoc nominating committee to consider
whether to accept or reject such resignations. The Corporation will
announce the results of the ad hoc nominating committee's
recommendation and board's determination once this matter has been
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead
theranostics product (Toraymyxin) for the treatment of septic shock.
Toraymyxin is a therapeutic hemoperfusion device that removes
endotoxin, which can cause sepsis, from the bloodstream. Directed by
the Company's Endotoxin Activity Assay (EAA™), the only FDA-cleared
diagnostic for the risk of developing sepsis, Spectral's EUPHRATES
trial is the world's first theranostics trial in the area of sepsis.
Spectral is listed on the Toronto Stock Exchange under the symbol SDI,
and on the OTC QX under the symbol DIAGF. For more information please
Information in this news release that is not current or historical
factual information may constitute forward looking information within
the meaning of securities laws. Implicit in this information,
particularly in respect of the future outlook of Spectral and
anticipated events or results, are assumptions based on beliefs of
Spectral's senior management as well as information currently available
to it. While these assumptions were considered reasonable by Spectral
at the time of preparation, they may prove to be incorrect.
Readers are cautioned that actual results are subject to a number of
risks and uncertainties, including the availability of funds and
resources to pursue R&D projects, the successful and timely completion
of clinical studies, the ability of Spectral to take advantage of
business opportunities in the biomedical industry, the granting of
necessary approvals by regulatory authorities as well as general
economic, market and business conditions, and could differ materially
from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
SOURCE: Spectral Diagnostics Inc.
For further information:
Spectral Diagnostics Inc.
Executive Vice President and CFO
416-626-3233 ext. 2200
416-815-0700 ext. 225